Biomerica, Inc.

Equities

BMRA

US09061H3075

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6652 ^USD	-1.50%		-8.91%	-46.78%

Apr. 15	Biomerica Provides Update on inFoods IBS Expansion	CI
Apr. 12	Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

February 21, 2024 at 08:19 am EST

Biomerica, Inc. announced the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, ?LabCorp?, brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world?s largest diagnostics clinical laboratories, boasting $7 billion in annual revenues, over 2,000 locations, and a workforce of 36,000 employees.

Latest news about Biomerica, Inc.

Biomerica Provides Update on inFoods IBS Expansion	Apr. 15	CI
Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 12	CI
Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board	Feb. 21	CI
Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors	Jan. 23	CI
Biomerica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 16	CI
Top Premarket Decliners	Dec. 19	MT
Biomerica Shares Rise After FDA 510(k) Clearance for H Pylori Bacteria Test	Dec. 18	DJ
Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria	Dec. 18	CI
Biomerica, Inc. Expands in Foods IBS Reach with Addition of Several New GI Groups	Nov. 08	CI
Biomerica, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-12	CI
Biomerica Says Dubai Approves Insurance Reimbursement for Colorectal Disease Screening Test	23-09-26	MT
Jack Kenny Joins Biomerica?S Board of Directors	23-08-28	CI
Biomerica, Inc. Reports Earnings Results for the Full Year Ended May 31, 2023	23-08-25	CI
Biomerica's Colorectal Disease Screening Test to be Available in CVS Stores in September	23-08-03	MT
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Growth Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Growth Index	23-06-23	CI
Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients	23-06-21	CI
Certain Stock Options of Biomerica, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	23-05-31	CI
Certain Common Stock of Biomerica, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	23-05-31	CI
Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome	23-05-18	CI
Biomerica, Inc. Announces inFoods IBS Test Now Available at Gastro Health	23-04-17	CI
Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	23-04-14	CI
Biomerica, Inc. Announces the Launch of InFoods IBS as a Laboratory Developed Test	23-03-08	CI

Chart Biomerica, Inc.

Duration

Period

More charts

Company Profile

Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physiciansâ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Companyâs two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIOMERICA, INC.	-46.78%	11.19M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution